EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. (2021)
Attributed to:
Cutaneous Immunology
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/all.14690
PubMed Identifier: 33538044
Publication URI: http://europepmc.org/abstract/MED/33538044
Type: Journal Article/Review
Volume: 76
Parent Publication: Allergy
Issue: 4
ISSN: 0105-4538